Develops CRISPR gene-editing medicines for people with serious diseases and licenses gene-editing technology to pharmaceutical and biotechnology partners.
10-K for FY2025, filed Mar 9, 2026We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of…View ↗
We are pursuing the right combination of gene editing and targeted delivery tools through internal development and the in-licensing of…View ↗
We are also leveraging our gene editing technology to drive the development of CRISPR-based medicines in therapeutic areas outside of our…View ↗
In addition, we are leveraging our intellectual property portfolio to drive potential out-licensing opportunities that can provide…View ↗
Partners pay upfront for licenses, reimburse research and development work, and may make additional payments when development, regulatory, or sales milestones are reached; royalties are tied to licensed-product sales.
10-K for FY2025, filed Mar 9, 2026The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company enters into…View ↗
The Company’s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method…View ↗
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to…View ↗
$40.5M
10-K for FY2025, filed Mar 9, 2026
$40.5M ↗
Pharmaceutical and biotechnology companies collaborate with Editas to develop gene-edited medicines or license gene-editing rights; relationships described include Bristol Myers Squibb/Juno Therapeutics, Immatics, and Vertex.
10-K for FY2025, filed Mar 9, 2026
No. It lost $160.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$23.4MView ↗
8-K, filed Apr 7, 2026
On April 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Editas Medicine, Inc. (the “Company”) (i)…View ↗
Growing. Revenue grew 59% in 4 years, from $25.5M in FY2021 to $40.5M in FY2025, about 12% a year.
From ex vivo to in vivo
The older report centered on an ex vivo HSC medicine for sickle cell disease and beta thalassemia, alongside next-generation in vivo work. The latest report says it stopped pursuing reni-cel commercialization and centers development on an in vivo treatment for hyperlipidemia.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Mar 9, 2026In September 2025, we announced the nomination of our lead in vivo development candidate, EDIT-401, an experimental, potential…View ↗
We also previously demonstrated proof-of-concept of our functional upregulation strategy in our former clinical trials of renizgamglogene…View ↗
In September 2025, we announced the nomination of our lead in vivo development candidate, EDIT-401, an experimental, potential…View ↗
Competes with AccurEdit Therapeutics, CRISPR Therapeutics, Eli Lilly, EmendoBio, nChroma Bio, Scribe Therapeutics, Tune Therapeutics, Yoltech Therapeutics, Amgen, Arrowhead Therapeutics, LIB Therapeutics, Merck, NewAmsterdam Pharma, Novartis, Regeneron Pharmaceuticals, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, and Sarepta Therapeutics
10-K for FY2025, filed Mar 9, 2026We compete in the segments of the pharmaceutical, biotechnology, and other related markets that utilize technologies encompassing genomic…View ↗
Loading...